RxDoctor Payments Data

Luke Cunningham, MD

Advanced Heart Failure and Transplant Cardiology · Oklahoma City, OKNPI 1649590134

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AstraZeneca at 53.7% of the total.

$69,641in general payments, 2019–2025

Across 385 payments — averaging $180.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$37K
  • Abbott$28K
  • Pfizer$973
  • Abiomed$635
  • Alnylam Pharmaceuticals Inc.$513
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$499
  • plus $2K from 17 others
$10,256in research payments, 2019–2025

Across 7 payments — averaging $1465.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vifor (international) Ltd.$7K
  • Abbott$3K

What the payments were for

  • Consulting fees$20,36929%
  • Speaking & faculty fees$35,95052%
  • Travel & lodging$2,8754%
  • Food & beverage$10,39115%
  • Education$310%
  • Entertainment$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$95,474
Medicare patients
390
Services billed
1,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan281$327,230
FarxigaDapagliflozin Propanediol194$188,599
EliquisApixaban103$110,023
JardianceEmpagliflozin103$98,211
CamzyosMavacamten12$96,013
XareltoRivaroxaban19$19,171
OzempicSemaglutide13$12,455
Repatha SureclickEvolocumab12$6,746
Torsemide128$5,619
DapagliflozinDapagliflozin Propanediol12$5,359
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine17$4,423
Metoprolol Succinate218$4,004
Potassium Chloride158$3,035
Carvedilol196$2,655
Atorvastatin Calcium185$2,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$465$327,230281 claims
AstraZenecaFarxiga$37,422$188,599194 claims
PfizerEliquis$973$110,023103 claims
Boehringer IngelheimJardiance$24$98,211103 claims
E.r. Squibb & Sons, L.L.C.Camzyos$245$96,01312 claims
Johnson & JohnsonXarelto$24$19,17119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →